SOLARAPharmaceuticals
Solara Active Pharma Sciences Ltd — Profit & Loss Statement
₹425.55
-3.05%
Solara Active Pharma Sciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | -57.05 Cr | 0.12 Cr | -1.37 Cr | — |
| Tax Rate For Calcs | 0.00 | 0.30 | 0.30 | 0.36 | — |
| Normalized EBITDA | 214.60 Cr | -89.81 Cr | 149.36 Cr | 92.30 Cr | — |
| Total Unusual Items | 0.00 | -190.17 Cr | 0.39 Cr | -3.80 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | -190.17 Cr | 0.39 Cr | -3.80 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 0.54 Cr | -567.39 Cr | -22.18 Cr | -58.15 Cr | — |
| Reconciled Depreciation | 99.25 Cr | 103.33 Cr | 111.19 Cr | 112.32 Cr | — |
| Reconciled Cost Of Revenue | 626.41 Cr | 805.02 Cr | 813.22 Cr | 681.32 Cr | — |
| EBITDA | 214.60 Cr | -279.98 Cr | 149.75 Cr | 88.50 Cr | — |
| EBIT | 115.35 Cr | -383.31 Cr | 38.56 Cr | -23.82 Cr | — |
| Net Interest Income | -114.81 Cr | -105.11 Cr | -80.86 Cr | -62.38 Cr | — |
| Interest Expense | 114.81 Cr | 105.11 Cr | 83.38 Cr | 67.28 Cr | — |
| Normalized Income | 0.54 Cr | -434.27 Cr | -22.45 Cr | -55.72 Cr | — |
| Net Income From Continuing And Discontinued Operation | 0.54 Cr | -567.39 Cr | -22.18 Cr | -58.15 Cr | — |
| Total Expenses | 1.18K Cr | 1.49K Cr | 1.35K Cr | 1.26K Cr | — |
| Diluted Average Shares | 3.86 Cr | 3.82 Cr | 3.91 Cr | 3.90 Cr | — |
| Basic Average Shares | 3.86 Cr | 3.82 Cr | 3.91 Cr | 3.90 Cr | — |
| Diluted EPS | 0.14 | -148.51 | -5.68 | -14.91 | — |
| Basic EPS | 0.14 | -148.51 | -5.68 | -14.91 | — |
| Diluted NI Availto Com Stockholders | 0.54 Cr | -567.39 Cr | -22.18 Cr | -58.15 Cr | — |
| Net Income Common Stockholders | 0.54 Cr | -567.39 Cr | -22.18 Cr | -58.15 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 0.54 Cr | -567.39 Cr | -22.18 Cr | -58.15 Cr | — |
| Minority Interests | 0.00 | 0.43 Cr | 0.07 Cr | 0.14 Cr | — |
| Net Income Including Noncontrolling Interests | 0.54 Cr | -566.96 Cr | -22.25 Cr | -58.29 Cr | — |
| Net Income Continuous Operations | 0.54 Cr | -566.96 Cr | -22.25 Cr | -58.29 Cr | — |
| Tax Provision | 0.00 | 78.54 Cr | -22.57 Cr | -32.81 Cr | — |
| Pretax Income | 0.54 Cr | -488.42 Cr | -44.82 Cr | -91.10 Cr | — |
| Other Non Operating Income Expenses | 8.32 Cr | 5.37 Cr | 5.64 Cr | 7.63 Cr | — |
| Special Income Charges | 0.00 | -190.17 Cr | 0.39 Cr | -3.80 Cr | — |
| Write Off | 0.00 | 122.81 Cr | 0.00 | 8.82 Cr | — |
| Impairment Of Capital Assets | 0.00 | 4.86 Cr | 0.00 | — | — |
| Net Non Operating Interest Income Expense | -114.81 Cr | -105.11 Cr | -80.86 Cr | -62.38 Cr | — |
| Interest Expense Non Operating | 114.81 Cr | 105.11 Cr | 83.38 Cr | 67.28 Cr | — |
| Operating Income | 107.03 Cr | -198.51 Cr | 33.16 Cr | -29.83 Cr | — |
| Operating Expense | 550.32 Cr | 682.41 Cr | 532.81 Cr | 579.06 Cr | — |
| Other Operating Expenses | 239.38 Cr | 335.16 Cr | 200.99 Cr | 200.65 Cr | — |
| Depreciation And Amortization In Income Statement | 99.25 Cr | 103.33 Cr | 111.19 Cr | 112.32 Cr | — |
| Depreciation Income Statement | 99.25 Cr | 103.33 Cr | 95.50 Cr | 97.05 Cr | — |
| Gross Profit | 657.35 Cr | 483.90 Cr | 565.97 Cr | 549.23 Cr | — |
| Cost Of Revenue | 626.41 Cr | 805.02 Cr | 813.22 Cr | 681.32 Cr | — |
| Total Revenue | 1.28K Cr | 1.29K Cr | 1.38K Cr | 1.23K Cr | — |
| Operating Revenue | 1.28K Cr | 1.29K Cr | 1.38K Cr | 1.23K Cr | — |
| Interest Income | — | 2.22 Cr | 5.78 Cr | 7.76 Cr | 14.22 Cr |
| Rent Expense Supplemental | — | 2.76 Cr | 1.29 Cr | 2.49 Cr | 2.97 Cr |
| Other Special Charges | — | 62.50 Cr | -0.39 Cr | 0.31 Cr | -2.27 Cr |
| Total Other Finance Cost | — | 5.05 Cr | 3.26 Cr | 2.86 Cr | 4.14 Cr |
| Interest Income Non Operating | — | 2.22 Cr | 5.78 Cr | 7.76 Cr | 14.22 Cr |
| Amortization | — | 13.24 Cr | 15.69 Cr | 15.27 Cr | 14.17 Cr |
| Selling General And Administration | — | 58.51 Cr | 55.33 Cr | 65.05 Cr | 64.80 Cr |
| Selling And Marketing Expense | — | 34.18 Cr | 31.68 Cr | 30.28 Cr | 31.88 Cr |
| General And Administrative Expense | — | 24.33 Cr | 23.65 Cr | 34.77 Cr | 32.92 Cr |
| Rent And Landing Fees | — | 2.76 Cr | 1.29 Cr | 2.49 Cr | 2.97 Cr |
| Restructuring And Mergern Acquisition | — | — | 0.00 | 3.49 Cr | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Solara Active Pharma Sciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.